These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2459027)

  • 21. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin.
    Braun PJ; Dennis S; Hofsteenge J; Stone SR
    Biochemistry; 1988 Aug; 27(17):6517-22. PubMed ID: 3146347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
    J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory mechanism of serpins. Identification of steps involving the active-site serine residue of the protease.
    Stone SR; Le Bonniec BF
    J Mol Biol; 1997 Jan; 265(3):344-62. PubMed ID: 9018048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of fragments of hirudin to investigate thrombin-hirudin interaction.
    Dennis S; Wallace A; Hofsteenge J; Stone SR
    Eur J Biochem; 1990 Feb; 188(1):61-6. PubMed ID: 2180697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant hirudin: genetic engineering and structure analysis.
    Märki WE; Grossenbacher H; Grütter MG; Liersch MH; Meyhack B; Heim J
    Semin Thromb Hemost; 1991 Apr; 17(2):88-93. PubMed ID: 1771417
    [No Abstract]   [Full Text] [Related]  

  • 26. Directed evolution towards protease-resistant hirudin variants.
    Wirsching F; Keller M; Hildmann C; Riester D; Schwienhorst A
    Mol Genet Metab; 2003 Dec; 80(4):451-62. PubMed ID: 14654359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calculation of relative binding free energies and configurational entropies: a structural and thermodynamic analysis of the nature of non-polar binding of thrombin inhibitors based on hirudin55-65.
    Wang J; Szewczuk Z; Yue SY; Tsuda Y; Konishi Y; Purisima EO
    J Mol Biol; 1995 Oct; 253(3):473-92. PubMed ID: 7473728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thermodynamic investigation of hirudin binding to the slow and fast forms of thrombin: evidence for folding transitions in the inhibitor and protease coupled to binding.
    Ayala YM; Vindigni A; Nayal M; Spolar RS; Record MT; Di Cera E
    J Mol Biol; 1995 Nov; 253(5):787-98. PubMed ID: 7473752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-hirudin monoclonal antibodies directed toward discontinuous epitopes of the hirudin amino-terminal and epitopes involving the carboxy-terminal hirudin amino acids.
    Koch C; Whitechurch O; Cordier P; Roitsch C
    Anal Biochem; 1993 Oct; 214(1):301-12. PubMed ID: 7504411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probing the structure of hirudin from Hirudinaria manillensis by limited proteolysis. Isolation, characterization and thrombin-inhibitory properties of N-terminal fragments.
    Vindigni A; De Filippis V; Zanotti G; Visco C; Orsini G; Fontana A
    Eur J Biochem; 1994 Dec; 226(2):323-33. PubMed ID: 8001550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiae.
    Lehman ED; Joyce JG; Bailey FJ; Markus HZ; Schultz LD; Dunwiddie CT; Jacobson MA; Miller WJ
    Protein Expr Purif; 1993 Jun; 4(3):247-55. PubMed ID: 8518563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antithrombin activity of the hirudin N-terminal core domain residues 1-43.
    Chang JY; Schlaeppi JM; Stone SR
    FEBS Lett; 1990 Jan; 260(2):209-12. PubMed ID: 2404798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preparation of monoclonal antibodies to hirudin and hirudin peptides. A method for studying the hirudin--thrombin interaction.
    Schlaeppi JM; Vekemans S; Rink H; Chang JY
    Eur J Biochem; 1990 Mar; 188(2):463-70. PubMed ID: 1690651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The structure of a complex of recombinant hirudin and human alpha-thrombin.
    Rydel TJ; Ravichandran KG; Tulinsky A; Bode W; Huber R; Roitsch C; Fenton JW
    Science; 1990 Jul; 249(4966):277-80. PubMed ID: 2374926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comeback of hirudin--an old-established anticoagulant agent.
    Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):10-23. PubMed ID: 2459000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structure-function relationships of the C-terminal functional domain of hirudin and its variants.
    Krstenansky JL; Mao SJ
    Blood Coagul Fibrinolysis; 1991 Feb; 2(1):91-6. PubMed ID: 1773003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thrombin interactions with hirudin.
    Fenton JW
    Semin Thromb Hemost; 1989 Jul; 15(3):265-8. PubMed ID: 2688098
    [No Abstract]   [Full Text] [Related]  

  • 38. Mapping of the thrombin des-ETW conformation by using site-directed mutants of hirudin. Evidence for the induction of nonlocal modifications by mutagenesis.
    Le Bonniec BF; Betz A; Guinto ER; Esmon CT; Stone SR
    Biochemistry; 1994 Apr; 33(13):3959-66. PubMed ID: 8142400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Biochemical and pharmacological aspects of the thrombin inhibitor hirudin].
    Walsmann P; Markwardt F
    Pharmazie; 1981 Oct; 36(10):653-60. PubMed ID: 7031705
    [No Abstract]   [Full Text] [Related]  

  • 40. Thrombin-bound conformation of a cyclic anticoagulant peptide using transferred nuclear Overhauser effect (NOE), distance geometry, and NOE simulations.
    Ning Q; Ripoll DR; Szewczuk Z; Konishi Y; Ni F
    Biopolymers; 1994 Sep; 34(9):1125-37. PubMed ID: 7948726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.